SCHEMBL2086903

SCHEMBL2086903

C[Si](C)(C)[Si](C)(C)C.[NaH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49955 0.91
Nitrogen SCHEMBL27656846 0.87
SCHEMBL27839446 0.83
SCHEMBL27816261 0.83
SCHEMBL27735222 0.83
Methane SCHEMBL28861313 0.83
SCHEMBL2235964 0.83 ALDH1A1 (0.33)
SCHEMBL27750254 0.83
SCHEMBL1549115 0.83
SCHEMBL182511 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107383005-A The preparation method of the acetic acid of 6 methyl 2 (4 aminomethyl phenyl) imidazo [1,2 a] pyridine 3 华东理工大学 2017-11-24 CN claimed
CN-108473483-A Compound for medical applications 澳大利亚生物医学公司 2018-08-31 CN disclosed
CN-107383005-A The preparation method of the acetic acid of 6 methyl 2 (4 aminomethyl phenyl) imidazo [1,2 a] pyridine 3 华东理工大学 2017-11-24 CN disclosed
US-9133073-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2015-09-15 US disclosed
US-8604083-B2 Method for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2013-12-10 US disclosed
US-20130281705-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2013-10-24 US disclosed
EP-1461323-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2013-10-09 EP disclosed
US-8552062-B2 Methods for the treatment of metabolic disorders such as diabetes WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-08 US disclosed
US-8487000-B2 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis Wellstat Therapertics Corporation (US) 2013-07-16 US disclosed
CN-101128469-B Protease inhibitor precursor synthesis TIBOTEC PHARM LTD 2012-11-14 CN disclosed
EP-1224168-A1 ANTIFUNGAL ENEDIYNES PHYTERA, INC. (US) 2002-07-24 EP disclosed
CN-1347420-A Growth-promoting hormone secretagogues LILLY CO ELI (US) 2002-05-01 CN disclosed
EP-1060172-A4 SYNTHESIS OF PACLITAXEL BACCATIN III BY PROTECTING THE 7-HYDROXYL USING A STRONG BASE AND AN ELECTROPHILE BRISTOL MYERS SQUIBB CO (US) 2001-10-24 EP disclosed
US-6307071-B1 Synthesis of paclitaxel from baccatin III by protection of the 7-hydroxyl of baccatin III using a strong base and an electrophile BRISTOL-MYERS SQUIBB COMPANY 2001-10-23 US disclosed
CN-1305473-A N,N-disubstituded amide for inhibit binding of integrins to their receptors protein TEXAS BIOTECHNOLOGY CORP (US) 2001-07-25 CN disclosed
US-6242583-B1 COUPLING CARBOHYDRATE COMPOUNDS IN PRESENCE OF PROMOTER TO A FUNCTIONALIZED SOLID SUPPORT BASF AKTIENGESELLSCHAFT (DE) 2001-06-05 US disclosed
WO-2001025197-A1 ANTIFUNGAL ENEDIYNES PHYTERA, INC. (US) 2001-04-12 WO disclosed
EP-1060172-A1 SYNTHESIS OF PACLITAXEL BACCATIN III BY PROTECTING THE 7-HYDROXYL USING A STRONG BASE AND AN ELECTROPHILE BRISTOL-MYERS SQUIBB COMPANY (US) 2000-12-20 EP disclosed
US-6020507-A Synthesis of paclitaxel from baccatin III by protection of the 7-hydroxyl of baccatin III using a strong base and an electrophile BRISTOL-MYERS SQUIBB COMPANY (US) 2000-02-01 US disclosed
WO-1999045001-A1 SYNTHESIS OF PACLITAXEL BACCATIN III BY PROTECTING THE 7-HYDROXYL USING A STRONG BASE AND AN ELECTROPHILE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-09-10 WO disclosed